“Candida albicans has been the prominent species causing vaginal yeast infections, however, we are seeing a notable shift in the etiology candidiasis with non-albicans Candida species gaining prominence,” Scynexis Vice President, Clinical Development and Medical Affairs Nkechi Azie, MD, said.

As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy?

A company called Vaxart is developing a COVID-19 vaccine that comes in the form of a tablet that could be stored at room temperature and even mailed to people at home.

Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders.

The company spent roughly three months looking at potential locations for its global headquarters, including Boston and the Washington, D.C., region.

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic diseases by achieving superior long-term disease remission through resetting the immune system.

Scynexis announced in October that it submitted a new drug application to the FDA for ibrexafungerp for the treatment of vulvovaginal candidiasis. The target action date is set for June 1, 2021. According to the company’s website, another phase 3 trial investigating the efficacy of ibrexafungerp in preventing recurrent vulvovaginal candidiasis is ongoing.